ARA-290 dosage: reported doses and schedule

Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.

Also called: Cibinetide, ARA 290, ARA290, pHBSP, pHSBP, Pyroglutamate helix B surface peptide.

Healing and repair peptides · EPO-derived peptide designed to activate the innate repair receptor.

Typical reported dose: 4 mg once a day for 4 weeks

  • First pilot: three IV doses: 2 mg every two days for three doses every two days for three doses, into a vein. Studied in a trial. Studied in: 20 adults with sarcoidosis or diabetes and neuropathic symptoms. (source)
  • Drug levels: 2 mg IV: 2 mg as a single dose as a single dose, into a vein. Studied in a trial. Studied in: 10 healthy volunteers in a crossover PK study. (source)
  • Drug levels: 2 mg under the skin: 2 mg as a single dose as a single dose, under the skin. Studied in a trial. Studied in: 10 healthy volunteers in a crossover PK study. (source)
  • Drug levels: 4 mg under the skin: 4 mg as a single dose as a single dose, under the skin. Studied in a trial. Studied in: 10 healthy volunteers in a crossover PK study. (source)
  • Drug levels: 6 mg under the skin: 6 mg as a single dose as a single dose, under the skin. Studied in a trial. Studied in: 10 healthy volunteers in a crossover PK study. (source)
  • Sarcoidosis: 2 mg IV three days a week: 2 mg on Monday, Wednesday and Friday on Monday, Wednesday and Friday, into a vein. Studied in a trial. Studied in: Adults with sarcoidosis and painful small-fiber neuropathy symptoms. (source)

Highest studied: 8 mg subcutaneous once daily for 28 days; not a safe personal maximum..

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

Related to ARA-290

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.